PTC Therapeutics Files 8-K Report
Ticker: PTCT · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1070081
Sentiment: neutral
Topics: 8-K, financial-statements, filing
TL;DR
PTC Therapeutics filed an 8-K, mostly procedural stuff, no major news yet.
AI Summary
On October 18, 2024, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates that PTC Therapeutics is adhering to its reporting obligations with the SEC, providing updates on its financial status and any relevant disclosures.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for financial statements and exhibits, not indicating any immediate material risks.
Key Players & Entities
- PTC THERAPEUTICS, INC. (company) — Filer
- 0001558370-24-013387 (other) — Accession Number
- October 18, 2024 (date) — Date of Report
- 500 Warren Corporate Center Drive (address) — Principal Executive Offices
- Warren, NJ 07059 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, and to make a Regulation FD disclosure.
When was this 8-K report filed?
This 8-K report was filed on October 18, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 500 Warren Corporate Center Drive, Warren, NJ 07059.
What is PTC Therapeutics, Inc.'s IRS Employer Identification Number?
PTC Therapeutics, Inc.'s IRS Employer Identification Number is 04-3416587.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-10-18 06:35:59
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
Filing Documents
- tmb-20241018x8k.htm (8-K) — 43KB
- tmb-20241018xex99d1.htm (EX-99.1) — 19KB
- tmb-20241018xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-013387.txt ( ) — 196KB
- tmb-20241018.xsd (EX-101.SCH) — 4KB
- tmb-20241018_def.xml (EX-101.DEF) — 3KB
- tmb-20241018_lab.xml (EX-101.LAB) — 16KB
- tmb-20241018_pre.xml (EX-101.PRE) — 9KB
- tmb-20241018x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 18, 2024, PTC Therapeutics, Inc. issued a press release announcing that the Committee for Medicinal Products for Human Use of the European Medicines Agency maintained its negative opinion for the renewal of the conditional marketing authorization for Translarna TM (ataluren) following reexamination, furnished as Exhibit 99.1 to this Report. The information in this Item 7.01 of this Report, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 18, 2024 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: October 18, 2024 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer